• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Peroxiredoxin-like 2A (PRXL2A)

ACP10752

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP10752 Target NameFAM213A
Target SynonymsC10orf58; CJ058_HUMAN; UPF0765 protein C10orf58FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-229
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9BRX8
Background Information
  • Uniprot Id

    Q9BRX8

  • Target Species

    Human

  • Target Name

    PRXL2A

  • Target Full Name

    Peroxiredoxin-like 2A

  • Target Function

    Involved in redox regulation of the cell. Acts as an antioxidant. Inhibits TNFSF11-induced NFKB1 and JUN activation and osteoclast differentiation. May affect bone resorption and help to maintain bone mass. Acts as a negative regulator of macrophage-mediated inflammation by inhibiting macrophage production of inflammatory cytokines, probably through suppression of the MAPK signaling pathway.

  • Target Subcellular Location

    Cytoplasm. Secreted.

  • Target Protein Families

    Peroxiredoxin-like FAM213 family, FAM213A subfamily

  • Target Tissue Specificity

    Expressed in CSF1 and TNFSF11-stimulated CD14(+) peripheral blood mononuclear cells (PBMCs).

  • Target Research Area

    Cancer

  • Target Synonyms

    C10orf58; CJ058_HUMAN; UPF0765 protein C10orf58

Inquire Recombinant Human Peroxiredoxin-like 2A (PRXL2A) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification